latest update:
[TrialBase DB]

trial summary · NCT07897344

Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy

A Pilot Trial of Controlled Feeding With Reduced Dietary Protein in Patients With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Trial record from the TrialBase DB dataset, status RECRUITING, condition Breast Cancer, sponsored by Josephine Connolly-Schoonen. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07897344phase —enrollment 15start 2026-11-02

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study will examine if a short-term, reduced protein diet for the 3-day period prior to and on the day of each of the first 4 chemotherapy cycles and 4 days prior to primary breast surgery is well tolerated and adhered to by patients with stage II or III estrogen receptor positive (ER+) human epidermal growth factor receptor negative (HER2-) breast cancer (BC) receiving neoadjuvant chemotherapy (NAC).

Source record: https://clinicaltrials.gov/study/NCT07897344

Facts

registry idNCT07897344
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionBreast Cancer
sponsorJosephine Connolly-Schoonen
sponsor classOTHER
enrollment15
start date2026-11-02
primary completion2028-10-30
completion2029-04-30
results postednot reported

Conditions

  • Breast Cancer
  • Hormone Receptor Positive / HER2-negative Breast Cancer

Interventions

  • Dietary Protein Intervention

Countries

  • United States

Intervention types: OTHER

Work with this record